Göran has more than 35 years of leadership and management experience in the biotech and pharmaceutical industry, with Board positions at several global companies, including currently as Chairman of Eyepoint Pharma, Tessa Therapeutics and Nanexa AB. Göran is also a director on the board of Selecta Biosciences. He began his career at Pfizer where he held several senior clinical positions both in the US and in Europe. Göran also served as President of the Astra Research Centre and held various senior appointments at GlaxoSmithKline.
In 1995, Göran joined Pharmacia as Executive Vice President and Deputy CEO to lead Research and Development with additional responsibilities for manufacturing, information technology, business development and M&A. During his nine-year tenure as Head of Research and Development at Pharmacia/Pharmacia & Upjohn, 17 new drugs were approved by the US FDA prior to Pharmacia’s acquisition by Pfizer for $60 billion.
Göran also served as CEO of Celltech Group (acquired by UCB for £1.5 billion) as well as Vice Chairman and Chairman of the Board of Directors of Novo Nordisk.
Göran is a qualified medical doctor and a founding fellow of the American College of Rheumatology in the US.